Indoco Remedies Ltd
Indoco Remedies Ltd (INDOCO) last reported results for the quarter ended Jun 2026, with sales of ₹468 crore and net profit of ₹65 crore. The stock last traded at ₹248, a market capitalisation of ₹2,292 crore. Over the past 52 weeks the stock has ranged between ₹162 and ₹317. Figures are as of 6 Oct 2026 and are not real time.
Indoco Remedies Ltd share price and key metrics
- Current price
- ₹248
- Market cap
- ₹2,292 cr
- Book value
- ₹102
- ROE
- -9.36%
- ROCE
- 0.96%
- Dividend yield
- 0.08%
- 52w high / low
- 317/162
Metrics as of 6 Oct 2026. Not real time.
Track Indoco Remedies Ltd
Cruxal reads every Indoco Remedies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Indoco Remedies Ltd growth and returns
- 10 Years
- 6%
- 5 Years
- 8%
- 3 Years
- 3%
- TTM
- 12%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 33%
- 10 Years
- -2%
- 5 Years
- -11%
- 3 Years
- -9%
- 1 Year
- -13%
- 10 Years
- 5%
- 5 Years
- 5%
- 3 Years
- -2%
- Last Year
- -9%
Indoco Remedies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹468 cr, up 6.4% from ₹440 cr a year earlier. Net profit turned positive at ₹65 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 433 | 411 | 390 | 440 | 485 | 445 | 476 | 468 |
| Expenses | 392 | 399 | 391 | 422 | 442 | 414 | 426 | 426 |
| Operating profit | 40 | 12 | -1 | 18 | 43 | 32 | 50 | 41 |
| OPM % | 9% | 2.9% | -0.2% | 4.0% | 9% | 7% | 10% | 9% |
| Other income | 2 | 2 | 2 | 2 | 0 | -5 | 4 | 100 |
| Interest | 18 | 16 | 18 | 26 | 25 | 26 | 46 | 28 |
| Depreciation | 29 | 29 | 29 | 30 | 32 | 32 | 32 | 35 |
| Profit before tax | -5 | -31 | -46 | -37 | -14 | -31 | -25 | 78 |
| Tax % | 107% | -8% | -9% | -1% | -32% | -6% | -5% | 16% |
| Net profit | -10 | -28 | -41 | -36 | -9 | -29 | -24 | 65 |
| EPS (₹) | -1.04 | -2.86 | -4.38 | -3.88 | -0.86 | -3.23 | -2.34 | 7.04 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Indoco Remedies Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,845 | 1,873 |
| Operating profit | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 100 | 142 | 165 |
| OPM % | 15% | 13% | 8% | 11% | 18% | 21% | 17% | 13% | 6% | 8% | 9% |
| Net profit | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -99 | 3 |
| EPS (₹) | 8.36 | 4.47 | -0.31 | 2.62 | 10.10 | 16.80 | 15.44 | 10.68 | -7.99 | -10.31 | 0.61 |
TTM is the trailing twelve months to the most recent quarter.
Indoco Remedies Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| Reserves | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,091 | 1,004 | 921 |
| Borrowings | 280 | 282 | 296 | 262 | 267 | 257 | 333 | 672 | 994 | 1,090 |
| Other liabilities | 266 | 281 | 301 | 330 | 279 | 325 | 297 | 363 | 414 | 564 |
| Total liabilities | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 |
| Fixed assets | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 | 997 | 1,193 |
| CWIP | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 | 321 | 90 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 1 | 1 |
| Other assets | 666 | 613 | 605 | 631 | 677 | 809 | 864 | 1,057 | 1,111 | 1,309 |
| Total assets | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 |
As reported by the company. Total assets equal total liabilities by construction.
Indoco Remedies Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 89 | 123 | 132 | 123 | 82 | 174 | 179 | 157 | 95 | 192 |
| Cash from investing | -171 | -135 | -104 | -56 | -67 | -121 | -208 | -433 | -339 | -102 |
| Cash from financing | 132 | -39 | -16 | -64 | -30 | -44 | 23 | 280 | 241 | -77 |
| Net cash flow | 50 | -51 | 12 | 3 | -14 | 8 | -7 | 4 | -3 | 14 |
| Free cash flow | -100 | -15 | 39 | 64 | 6 | 49 | -27 | -269 | -257 | 91 |
| CFO / operating profit | 72% | 98% | 177% | 103% | 45% | 66% | 84% | 76% | 112% | 139% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Indoco Remedies Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 12% | 7% | 1% | 6% | 16% | 23% | 17% | 10% | -0% | 1% |
| Debtor days | 74 | 73 | 74 | 69 | 69 | 70 | 77 | 82 | 77 | 97 |
| Inventory days | 189 | 203 | 209 | 230 | 245 | 248 | 228 | 230 | 307 | 273 |
| Days payable | 166 | 157 | 195 | 183 | 117 | 107 | 86 | 100 | 152 | 208 |
| Cash conversion cycle | 97 | 119 | 88 | 116 | 197 | 212 | 219 | 212 | 232 | 162 |
| Working capital days | 41 | 38 | 21 | 22 | 59 | 78 | 82 | 62 | 39 | 21 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Indoco Remedies Ltd shareholding pattern
Promoters held 58.86% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.27% and DIIs 17.68%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 58.76% | 58.80% | 58.90% | 58.90% | 58.90% | 58.90% | 58.86% | 58.86% |
| FIIs | 1.70% | 1.25% | 1.24% | 1.22% | 1.25% | 1.10% | 0.94% | 1.27% |
| DIIs | 18.25% | 18.91% | 18.75% | 18.96% | 18.16% | 18.15% | 18.15% | 17.68% |
| Public | 21.27% | 21.02% | 21.02% | 20.82% | 21.60% | 21.76% | 21.90% | 22.04% |
| No. of shareholders | 34,416 | 34,676 | 34,497 | 33,129 | 33,319 | 32,659 | 32,276 | 32,457 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Indoco Remedies Ltd corporate filings
- Attached the certificate issued by MUFG Intime India Private Ltd, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI(D & P) Regulations,2018 ....Company Updatelow impact
- Pursuant to Regulation 30 and Part A of Schedule III of SEBI (LODR) Regulations,2015, please find enclosed a copy of the letter dispatched to shareholders holding shares in physical mode, ....Company Updatelow impact
- Indoco Remedies Limited incorporates wholly owned subsidiary 'Warren Lifesciences Private Limited'Company Updatelow impact
Cruxal's analysis: Indoco Remedies Limited has announced the incorporation of a new wholly owned subsidiary…
Read the full analysis - Intimation regarding Closure of Trading WindowInsider Trading / SASTlow impact
- Indoco Remedies Ltd discloses ESG rating intimation under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: Indoco Remedies Ltd has submitted an intimation regarding its ESG (Environmental, Social…
Read the full analysis - Indoco Remedies Limited announces incorporation of new wholly owned subsidiary 'Warren Lifesciences Private Limited'Company Updatelow impact
Cruxal's analysis: Indoco Remedies Limited has received approval to incorporate a new wholly owned…
Read the full analysis - Indoco Remedies Limited concludes 79th AGM with shareholder approval for dividend and enhanced borrowing limitsAGM/EGMlow impact
Cruxal's analysis: Indoco Remedies Limited has successfully concluded its 79th Annual General Meeting held…
Read the full analysis - Indoco Remedies Limited Concludes 79th AGM; Seeks Shareholder Approval for Increased Borrowing LimitsAGM/EGMlow impact
Cruxal's analysis: Indoco Remedies Limited has concluded its 79th Annual General Meeting, where the company…
Read the full analysis - Indoco Remedies reports UK MHRA inspection at Goa Plant ICompany Updatemedium impact
Cruxal's analysis: Indoco Remedies has disclosed a regulatory inspection by the UK MHRA at its solid oral…
Read the full analysis - Indoco Remedies Promoters Increase Stake via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: Indoco Remedies Limited promoters, led by Aditi M. Panandikar, have increased their…
Read the full analysis - Indoco Remedies reports USFDA inspection at Goa Plant II (Sterile)Company Updatemedium impact
Cruxal's analysis: Indoco Remedies has disclosed a USFDA inspection at its manufacturing facility, Plant II…
Read the full analysis - Indoco Remedies Limited: Promoters Increase Stake via Open Market PurchaseInsider Trading / SASTlow impact
Cruxal's analysis: Indoco Remedies Limited promoters, Ms. Aditi M. Panandikar and Ms. Madhura Suresh Kare…
Read the full analysis - Indoco Remedies Limited: Promoter Group Increases Stake via Open Market PurchaseInsider Trading / SASTlow impact
Cruxal's analysis: Indoco Remedies Limited has reported that members of the promoter group, Ms. Aditi M…
Read the full analysis - Indoco Remedies executes Deed of Conveyance for sale of land plotCompany Updatelow impact
Cruxal's analysis: Indoco Remedies has formally executed a Deed of Conveyance for the sale of a plot of…
Read the full analysis - Indoco Remedies Ltd announces 79th Annual General Meeting and E-voting scheduleCompany Updatelow impact
Cruxal's analysis: Indoco Remedies Ltd has published a newspaper advertisement regarding the scheduling of…
Read the full analysis - Indoco Remedies Ltd files Business Responsibility and Sustainability Report (BRSR)Otherslow impact
Cruxal's analysis: Indoco Remedies Ltd has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Indoco Remedies Ltd releases Annual Report for the financial year 2025-2026Otherslow impact
Cruxal's analysis: Indoco Remedies Ltd has filed its Annual Report for the financial year 2025-2026 as per…
Read the full analysis - Indoco Remedies Limited Announces 79th Annual General Meeting and Releases Annual Report 2025-26AGM/EGMlow impact
Cruxal's analysis: Indoco Remedies Limited has issued a formal notice for its 79th Annual General Meeting…
Read the full analysis - Indoco Remedies Limited Announces 79th AGM and Declares Final Dividend of INR 0.20 per ShareAGM/EGMlow impact
Cruxal's analysis: Indoco Remedies Limited has scheduled its 79th Annual General Meeting for September 17…
Read the full analysis - Indoco Remedies Limited announces Record Date of 10th September 2026 for final dividend of 0.20 INR per shareCorp. Actionlow impact
Cruxal's analysis: Indoco Remedies Limited has formally notified the stock exchanges that 10th September…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.